CLHEP
We develop tumor-activated modular peptides that target HK2, a key enzyme of neoplastic growth, inducing cell death.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
About CLHEP
We develop tumor-activated modular peptides that target HK2, a key enzyme in neoplastic growth, inducing cell death. Key offerings include validated in vitro, ex vivo, in vivo the first peptide. A molecular deception against tumors. Next-generation peptides for more selective and safer oncological treatments. THE HK2pep TECHNOLOGY, a molecular 'Trojan horse', travels in an inactive form in the blood, remaining invisible to cells.
How CLHEP works
Business Model
Unspecified B2B model focused on the development of peptides for oncological treatments.
Products & Services
Key Products
- validato in vitro
- ex vivo
- in vivo Il primo peptide
- HK2pep
- è in fase di R&D preclinica non regolatoria
Market & Clients
Key Customers
A molecular deception against tumors New generation peptides for more selective and safe oncological treatments HK2pep TECHNOLOGY, molecular "Trojan horse" HK2pep travels in an inactive form in the blood, remaining invisible to cells
Geographic Presence
How CLHEP competes
Competitive Advantages
- Declared technological differentiation on the product.
Similar Startups
AIRIZON S.R.L.
Smart solutions for clean skies through intelligent air quality monitoring and environmental innovation.
Read AnalysisBIOCENTIS S.R.L.
Revolutionizing cell therapy and biotechnology with innovative research and therapeutic solutions.
Read AnalysisCOFFEEFROM S.R.L.
Innovative biopolymer blend using coffee grounds to create sustainable materials from agricultural waste.
Read AnalysisSources
- Clhep - Un inganno molecolare contro i tumori — clhep.com
- LinkedIn company page — LinkedIn